• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel.

作者信息

Plaks Vicki, Rossi John M, Chou Justin, Wang Linghua, Poddar Soumya, Han Guangchun, Wang Zixing, Kuang Shao-Qing, Chu Fuliang, Davis Richard E, Vega Francisco, Bashir Zahid, Jacobson Caron A, Locke Frederick L, Reagan Patrick M, Rodig Scott J, Lekakis Lazaros J, Flinn Ian W, Miklos David B, Bot Adrian, Neelapu Sattva S

机构信息

Kite, a Gilead Company, Santa Monica, CA.

The University of Texas MD Anderson Cancer Center, Houston, TX.

出版信息

Blood. 2021 Sep 23;138(12):1081-1085. doi: 10.1182/blood.2021010930.

DOI:10.1182/blood.2021010930
PMID:34041526
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8462361/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab43/8462361/e508b5989837/bloodBLD2021010930f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab43/8462361/c2863a1544b5/bloodBLD2021010930f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab43/8462361/e508b5989837/bloodBLD2021010930f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab43/8462361/c2863a1544b5/bloodBLD2021010930f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab43/8462361/e508b5989837/bloodBLD2021010930f2.jpg

相似文献

1
CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel.CD19靶点逃逸作为接受axi-cel治疗的大B细胞淋巴瘤复发机制
Blood. 2021 Sep 23;138(12):1081-1085. doi: 10.1182/blood.2021010930.
2
Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma.ZUMA-1 研究中高龄患者的结局，该研究为 axicabtagene ciloleucel 治疗难治性大 B 细胞淋巴瘤的关键研究。
Blood. 2020 Jun 4;135(23):2106-2109. doi: 10.1182/blood.2019004162.
3
Axicabtagene ciloleucel and brexucabtagene autoleucel in relapsed and refractory diffuse large B-cell and mantle cell lymphomas.阿基仑赛注射液和倍利妥注射液治疗复发/难治性弥漫性大 B 细胞淋巴瘤和套细胞淋巴瘤。
Future Oncol. 2021 Apr;17(11):1269-1283. doi: 10.2217/fon-2020-0291. Epub 2021 Jan 15.
4
Axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma patients in complete metabolic response.阿基仑赛注射液用于完全代谢缓解的复发或难治性大B细胞淋巴瘤患者。
Haematologica. 2023 Apr 1;108(4):1163-1167. doi: 10.3324/haematol.2022.281954.
5
Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL.阿基仑赛注射液，一种用于侵袭性非霍奇金淋巴瘤的一流嵌合抗原受体T细胞疗法。
Leuk Lymphoma. 2018 Aug;59(8):1785-1796. doi: 10.1080/10428194.2017.1387905. Epub 2017 Oct 23.
6
Development and Use of the Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Axicabtagene Ciloleucel in Large B-Cell Lymphoma: A Review.嵌合抗原受体 T 细胞疗法 Axicabtagene Ciloleucel 治疗大 B 细胞淋巴瘤的研发与应用：综述。
JAMA Oncol. 2020 Feb 1;6(2):281-290. doi: 10.1001/jamaoncol.2019.3869.
7
Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy.接受axi-cabtagene ciloleucel治疗后病情进展的大B细胞淋巴瘤患者的预后
Blood. 2021 Apr 1;137(13):1832-1835. doi: 10.1182/blood.2020006245.
8
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.阿基仑赛注射液治疗难治性大 B 细胞淋巴瘤的长期安全性和疗效（ZUMA-1）：一项单臂、多中心、1-2 期临床试验。
Lancet Oncol. 2019 Jan;20(1):31-42. doi: 10.1016/S1470-2045(18)30864-7. Epub 2018 Dec 2.
9
New Second-Line Treatment for B-Cell Lymphoma.新的 B 细胞淋巴瘤二线治疗方案。
Am J Nurs. 2022 Aug 1;122(8):23. doi: 10.1097/01.NAJ.0000854972.82263.fc.
10
Pembrolizumab-induced Remission After Failure of Axicabtagene Ciloleucel: Case Report and Literature Review.帕博利珠单抗治疗 axicabtagene ciloleucel 治疗失败后的缓解：病例报告及文献复习。
In Vivo. 2021 Nov-Dec;35(6):3401-3406. doi: 10.21873/invivo.12639.

引用本文的文献

1
Second Generation Tiancimycin-Based Antibody-Drug Conjugates Enabled by Highly Efficient Semi-synthetic Approach Specifically Targeting B-Cell Malignancies.基于高效半合成方法的第二代替考拉宁抗体药物偶联物特异性靶向B细胞恶性肿瘤。
JACS Au. 2025 Jul 1;5(7):3171-3181. doi: 10.1021/jacsau.5c00353. eCollection 2025 Jul 28.
2
Leveraging immunologically based therapies to treat diffuse large B-cell lymphoma.利用基于免疫的疗法治疗弥漫性大B细胞淋巴瘤。
Trends Cancer. 2025 Jul 23. doi: 10.1016/j.trecan.2025.06.013.
3
Allogeneic CAR-engineered cellular therapy for relapsed and refractory large B cell lymphoma: a systematic review and meta-analysis.

本文引用的文献

1
A Critical Role for Fas-Mediated Off-Target Tumor Killing in T-cell Immunotherapy.Fas 介导体外肿瘤杀伤在 T 细胞免疫治疗中的关键作用。
Cancer Discov. 2021 Mar;11(3):599-613. doi: 10.1158/2159-8290.CD-20-0756. Epub 2020 Dec 17.
2
Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma.肿瘤负荷、炎症和产品属性决定了阿基仑赛注射液治疗大B细胞淋巴瘤的疗效。
Blood Adv. 2020 Oct 13;4(19):4898-4911. doi: 10.1182/bloodadvances.2020002394.
3
Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial.
异基因嵌合抗原受体工程化细胞疗法治疗复发难治性大B细胞淋巴瘤：一项系统评价和荟萃分析。
Front Immunol. 2025 Jul 8;16:1585556. doi: 10.3389/fimmu.2025.1585556. eCollection 2025.
4
Pre-clinical safety and efficacy evaluation of Helicobacter Pylori neutrophil-activating protein (NAP)-armed CAR-T cells targeting B cell lymphomas.靶向B细胞淋巴瘤的幽门螺杆菌中性粒细胞激活蛋白（NAP）武装的嵌合抗原受体T细胞（CAR-T细胞）的临床前安全性和疗效评估。
Cancer Immunol Immunother. 2025 Jul 12;74(8):262. doi: 10.1007/s00262-025-04112-1.
5
CAR-T cells targeting CCR9 and CD1a for the treatment of T cell acute lymphoblastic leukemia.靶向CCR9和CD1a的嵌合抗原受体T细胞用于治疗T细胞急性淋巴细胞白血病。
J Hematol Oncol. 2025 Jul 1;18(1):69. doi: 10.1186/s13045-025-01715-0.
6
Therapeutic landscape of primary refractory and relapsed diffuse large B-cell lymphoma: Recent advances and emerging therapies.原发性难治性和复发性弥漫性大B细胞淋巴瘤的治疗前景：最新进展与新兴疗法
J Hematol Oncol. 2025 Jul 1;18(1):68. doi: 10.1186/s13045-025-01702-5.
7
SITC vision: Opportunities for deeper understanding of mechanisms of anti-tumor activity, toxicity, and resistance to optimize cancer immunotherapy.肿瘤免疫治疗学会愿景：有机会更深入了解抗肿瘤活性、毒性和耐药性机制，以优化癌症免疫治疗。
J Immunother Cancer. 2025 Jun 25;13(6):e011929. doi: 10.1136/jitc-2025-011929.
8
Clinical, tumor, and product features associated with outcomes after axicabtagene ciloleucel therapy in follicular lymphoma.在滤泡性淋巴瘤中，与axi-cabtagene ciloleucel治疗后结局相关的临床、肿瘤及产品特征。
J Clin Invest. 2025 Aug 15;135(16). doi: 10.1172/JCI181893.
9
[Modern systemic treatment-bispecific antibodies and CAR-T cell therapy : Clinical management, mechanisms of action, outcomes].[现代系统治疗——双特异性抗体与嵌合抗原受体T细胞疗法：临床管理、作用机制与疗效]
Radiologie (Heidelb). 2025 Jun 13. doi: 10.1007/s00117-025-01472-8.
10
Efficacy and safety of a novel CD19, CD22 dual-targeted fully human loop bi-CAR-T for the treatment of relapsed/refractory B cell non-Hodgkin lymphoma.一种新型CD19、CD22双靶点全人源环状双特异性嵌合抗原受体T细胞（bi-CAR-T）治疗复发/难治性B细胞非霍奇金淋巴瘤的疗效和安全性
J Transl Med. 2025 Jun 5;23(1):630. doi: 10.1186/s12967-025-06567-3.
双特异性抗 CD20、抗 CD19 CAR T 细胞治疗复发 B 细胞恶性肿瘤：1 期剂量递增和扩展试验。
Nat Med. 2020 Oct;26(10):1569-1575. doi: 10.1038/s41591-020-1081-3. Epub 2020 Oct 5.
4
Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B-cell lymphoma.优化的串联 CD19/CD20 CAR 工程化 T 细胞治疗难治/复发 B 细胞淋巴瘤。
Blood. 2020 Oct 1;136(14):1632-1644. doi: 10.1182/blood.2020005278.
5
Tuning the Antigen Density Requirement for CAR T-cell Activity.调整 CAR T 细胞活性的抗原密度要求。
Cancer Discov. 2020 May;10(5):702-723. doi: 10.1158/2159-8290.CD-19-0945. Epub 2020 Mar 19.
6
CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy.嵌合抗原受体 T 细胞疗法对 CD19 弱表达 B 淋巴细胞白血病有效，但会受到先前blinatumomab 治疗的影响。
Blood Adv. 2019 Nov 26;3(22):3539-3549. doi: 10.1182/bloodadvances.2019000692.
7
Fine Epitope Mapping of the CD19 Extracellular Domain Promotes Design.CD19 细胞外结构域的精细表位作图促进设计。
Biochemistry. 2019 Dec 3;58(48):4869-4881. doi: 10.1021/acs.biochem.9b00808. Epub 2019 Nov 21.
8
CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape.嵌合抗原受体 T 细胞 trogocytosis 和协同杀伤调节肿瘤抗原逃逸。
Nature. 2019 Apr;568(7750):112-116. doi: 10.1038/s41586-019-1054-1. Epub 2019 Mar 27.
9
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.阿基仑赛注射液治疗难治性大 B 细胞淋巴瘤的长期安全性和疗效（ZUMA-1）：一项单臂、多中心、1-2 期临床试验。
Lancet Oncol. 2019 Jan;20(1):31-42. doi: 10.1016/S1470-2045(18)30864-7. Epub 2018 Dec 2.
10
Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia.嵌合抗原受体 19 治疗急性淋巴细胞白血病中靶抗原丢失的遗传机制。
Nat Med. 2018 Oct;24(10):1504-1506. doi: 10.1038/s41591-018-0146-z. Epub 2018 Oct 1.